KRI 1314

Also Known As:

Cyclohexanebutanoic acid, alpha-hydroxy-beta-((3-(1H-imidazol-4-yl)-2-((4-(4-morpholinyl)-2-(1-naphthalenylmethyl)-1,4-dioxobutyl)amino)-1-oxopropyl)amino)-, 1-methylethyl ester; KRI-1314; isopropyl 3-(((N-(3-morpholinocarbonyl)-2-(1-naphthylmethyl)propionyl)histidyl)amino)-4-cyclohexyl-2-hydroxybutyrate; isopropyl 3-(N-(2-(1-naphthylmethyl)-3-(morpholinocarbonyl)propionyl)-L-histidyl)amino-4-cyclohexyl-2-hydroxybutyrate

Networked: 1 relevant articles (0 outcomes, 0 trials/studies)

Bio-Agent Context: Research Results

Related Diseases

Hypertension (High Blood Pressure)

04/01/1994 - "These results indicate that the potent human renin inhibitor KRI-1314 may become an orally effective drug for treating renin-dependent hypertension."
04/01/1994 - "In the sustained hypertension induced by continuous intravenous infusion of RH-renin (0.1 microgram/kg/min), a dose-dependent hypotensive response was produced by bolus intravenous injection of KRI-1314 (0.03-3 mg/kg). "

Related Drugs and Biologics

1.	Renin
2.	Renin Inhibitors

Related Therapies and Procedures

1.	Intravenous Injections
2.	Intravenous Infusions